CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

Stock Market Rally Pauses As Yields Rebound; Datadog, Affirm Among Earnings Winners: Weekly Review ↗

November 10, 2023

The major indexes ended long win streaks. Datadog led earnings winners.

These three companies have gene editing therapies in late-stage clinical trials, making them promising biotech stocks to buy right now.

3 Biotech Stocks That Are Betting on the Future of Gene Editing ↗

November 09, 2023

This Program for a Common Problem May Be Vertex Pharmaceuticals' Ticket to a New Wave of Billion-Dollar Revenues ↗

November 09, 2023

Vertex shares look cheap today considering all the company has to offer.

CRISPR's financial prospects could soon get an upgrade.

Why CRISPR Therapeutics Stock Could Be About to Take Off ↗

November 08, 2023

Gene correction technology took a big step forward this week.

Why CRISPR Therapeutics Stock Charged Northward This Week ↗

November 03, 2023

Many industry heavyweights are on the hunt for fresh new ideas -- great news for biotech stocks to buy with strong pipelines.

3 Biotech Stocks With the Strongest Clinical Pipelines ↗

November 08, 2023

On Wednesday, CRISPR Therapeutics stock had its Relative Strength (RS) Rating upgraded to 85, up from 68 a day earlier.

CRISPR Therapeutics Stock Earns IBD Stock Rating Upgrade ↗

November 08, 2023

Vertex stock is off its all-time highs after a slight miss on revenue, but the company's robust pipeline gives investors a reason to watch VRTX stock closely

Why you can make Vertex Pharmaceuticals a buy on any pullback

November 08, 2023

Via MarketBeat

Why CRISPR Therapeutics Stock Crushed the Market Today ↗

November 07, 2023

Investors were cheered by the company's latest earnings release, coupled with operational updates.

Vertex Slouches After Tech Leader Reports Mixed Results; But Late-Stage Pipeline In Focus ↗

November 07, 2023

The company expects $9.85 billion in full-year sales of its cystic fibrosis treatments.

Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners ↗

November 06, 2023

Roku vaulted 50% to become Ark Innovation's top holding.

CRISPR Therapeutics AG (NYSE: CRSP) shares are trading higher Monday after the company announced preclinical data for its investigational programs for the

Why CRISPR Therapeutics Stock Is Moving Higher Monday ↗

November 06, 2023

Via Benzinga

2 Magnificent Growth Stocks That Might Be Badly Mispriced Right Now ↗

November 05, 2023

These two beaten-down growth stocks could be brilliant buys for risk-tolerant investors.

Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review ↗

November 03, 2023

Bulls are back in control as the major indexes confirmed the uptrend this week.

Here's What Investors Need to Know About Vertex Pharmaceuticals and CRISPR Therapeutics' Big Day at the FDA ↗

November 03, 2023

The meeting went almost as well as could be expected.

Get these stocks while they're cheap.

3 Healthcare Stocks to Buy Hand Over Fist in November ↗

November 03, 2023

This stock could be a long-term winner, thanks to its game-changing technology.

One Month Ahead of its Most Crucial Moment Ever, Should You Buy CRISPR Therapeutics? ↗

November 02, 2023

Stocks are up today as investors prepare for the most recent information from the Federal Reserve concerning interest rates.

Why Are Stocks Up Today? ↗

November 01, 2023

Aldeyra Therapeutics stock is rising with heavy trading of ALDX shares after signing an exclusive option agreement with AbbVie.

Topics Economy

Why Is Aldeyra Therapeutics (ALDX) Stock Up 40% Today? ↗

November 01, 2023

The agency could soon approve a potential cure for sickle cell disease .

Crispr Therapeutics Rallies On Bullish Views Of First-Ever Gene-Editing Drug ↗

November 01, 2023

CRSP stock is rallying after an FDA panel appeared to view CRISPR Therapeutics' sickle-cell anemia treatment as safe.

CRSP Stock Alert: Can CRISPR Therapeutics Short Squeeze Higher? ↗

November 01, 2023

AMD, CRISPR Therapeutics, Paycom Software, DraftKings, Tesla: Why These 5 Stocks Are On Investors' Radars Today ↗

October 31, 2023

Major U.S. indices ended in the green on Tuesday, with the Dow gaining nearly 124 points or 0.4% to 33,052.87.

Via Benzinga

Topics Stocks

CRSP Stock Halt: CRISPR Trading Halted Ahead of FDA Decision ↗

October 31, 2023

Investors in CRISPR and CRSP stock have certainly been on a wild ride so far this year. Here's what investors need to watch right now.

Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient ↗

October 30, 2023

This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term.

Although CRISPR Therapeutics may have a breakthrough drug on its hands, regulatory concerns hang over CRSP stock.

CRSP Stock: FDA Considers Additional Review of CRISPR Therapeutics Gene Therapy ↗

October 27, 2023

Questions Surround Vertex/CRISPR's Sickle Cell Gene Therapy As FDA AdComm Meeting Approaches ↗

October 27, 2023

The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee will meet next

Via Benzinga

Vertex Pharmaceuticals: Buy at the High? ↗

October 26, 2023

Vertex shares have been flying high in recent times.

These stocks make great bargains today.

2 Fantastic Growth Stocks to Buy Hand Over Fist ↗

October 26, 2023

Neither has performed well on the stock market this year.

2 Biotech Stocks You Can Buy and Hold for the Next Decade ↗

October 25, 2023